Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Nuclear Medicine and Molecular Imaging|January 29, 2015
Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseasesAdrien Lebasnier, Guillaume Lamotte, Alain Manrique, et al.
The Lancet. Neurology|April 23, 2011
Stroke and the immune system: from pathophysiology to new therapeutic strategiesRichard Macrez, Carine Ali, Olivier Toutirais, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 20, 2020
Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective CohortPierre Branger, Jean-Jacques Parienti, Nathalie Derache, et al.
Bulletin De L'Academie Nationale De Medecine|September 10, 2005
[Perry and Purdy's syndrome (familial and fatal parkinsonism with hypoventilation and athymhormia)]Bernard Lechevalier, Françoise Chapon, Gilles Defer, et al.
Journal of the Neurological Sciences|November 5, 2011
CD49d expression as a promising biomarker to monitor natalizumab efficacyGilles Defer, Delphine Mariotte, Nathalie Derache, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 7, 2021
Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database AnalysisCharles Dolladille, Basile Chrétien, Laure Peyro-Saint-Paul, et al.
Multiple Sclerosis and Related Disorders|January 27, 2020
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patientsFloriane Calocer, Olivier Dejardin, Arnaud Kwiatkowski, et al.
Revue Neurologique|June 16, 2007
[Late onset Rasmussen's syndrome: clinical and therapeutic characteristics]V Jaillon-Riviere, S Dupont, Françoise Bertran, et al.
Drug Safety|October 13, 2020
Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled TrialGilles Defer, Sophie Fedrizzi, Damien Chevanne, et al.
Trials|March 11, 2018
Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trialGilles Defer, Florian Le Caignec, Sophie Fedrizzi, et al.
Pageof 9